Astrazeneca (AZN) Non Operating Income (2016 - 2025)
Historic Non Operating Income for Astrazeneca (AZN) over the last 15 years, with Q1 2025 value amounting to -$265.0 million.
- Astrazeneca's Non Operating Income rose 1225.17% to -$265.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $1.4 billion, marking a year-over-year increase of 17463.01%. This contributed to the annual value of $1.3 billion for FY2025, which is 389.41% up from last year.
- Latest data reveals that Astrazeneca reported Non Operating Income of -$265.0 million as of Q1 2025, which was up 1225.17% from $2.2 billion recorded in Q4 2024.
- In the past 5 years, Astrazeneca's Non Operating Income ranged from a high of $2.2 billion in Q4 2024 and a low of -$945.0 million during Q4 2023
- In the last 5 years, Astrazeneca's Non Operating Income had a median value of -$287.0 million in 2023 and averaged -$84.8 million.
- As far as peak fluctuations go, Astrazeneca's Non Operating Income plummeted by 1272.08% in 2022, and later surged by 33312.17% in 2024.
- Over the past 5 years, Astrazeneca's Non Operating Income (Quarter) stood at -$283.0 million in 2021, then decreased by 12.72% to -$319.0 million in 2022, then plummeted by 196.24% to -$945.0 million in 2023, then soared by 333.12% to $2.2 billion in 2024, then tumbled by 112.03% to -$265.0 million in 2025.
- Its Non Operating Income stands at -$265.0 million for Q1 2025, versus $2.2 billion for Q4 2024 and -$274.0 million for Q3 2024.